What to Do Now After OIG’s Special Fraud Alert

V2V President Dan Rehal sits down for a roundtable discussion with industry compliance expert and attorney, Brian Dahl (Dahl Compliance Consulting) and medical communications strategist and KOL expert, David Kendall, MD (Zealand Pharma) as they analyze what the OIG’s Special Fraud Alert on pharma dinner programs means for the future of peer-to-peer HCP education.

Vision2Voice Biopharma Healthcare Communications

Daniel Rehal, Vision2Voice Healthcare Communications
Special Guests:
Brian Dahl, Dahl Compliance Consulting LLC
David Kendall, MD, Zealand Pharma A/S

Enter Your Information To Watch This Webinar

Your Contact Information Is Secure And Will Never Be Shared, Rented Or Sold.

Who Should Watch:

Biopharma industry professionals strategizing and planning their healthcare communications strategies for 2021 amid the recent Special Fraud Alert from the OIG.

Your Host

Daniel J. Rehal, President, Vision2Voice

Dan founded Vision2Voice Healthcare Communications in 2008 to continue his passion of connecting healthcare professionals to the resources that improve patient care. Dan understands the pharmaceutical industry from the ground up. He has his BS and MBA from the University of Iowa spending his time studying pharmacy, chemistry, and business. He ascended the ranks at Merck early in his career and eventually assumed global responsibilities at Takeda. Dan has decades of experience in both marketing and sales roles supporting a multitude of pharmaceutical brands as an award-winning Sales Representative, Training Manager,Sales Leader,Sr. Product Manager, and Commercial Leader.

Special Guests

David Kendall, MD, Senior Global Medical Advisor – Metabolism, Global Medical Affairs, Zealand Pharma A/S

David M. Kendall, M.D., is a Senior Global Medical Advisor and a senior member of the Global Medical Affairs team at Zealand Pharma A/S. Dr. Kendall has more than 30 years of experience in diabetes research, education, clinical care and industry. His work has focused on the care and management of diabetes and its complications, and the treatment of cardiovascular, renal and metabolic diseases. He held a number of senior leadership roles in clinical and academic medicine and the biopharmaceutical industry including serving as Chief Medical Officer at MannKind Corporation, VP - Medical Affairs and Distinguished Medical Fellow - Lilly Diabetes, Chief Scientific and Medical Officer for the American Diabetes Association and Chief of Clinical Services and Medical Director at the International Diabetes Center and the University of Minnesota (1994-2008)

Brian Dahl, Owner Principal, Dahl Compliance Consulting LLC

Brian Dahl is the Principal at Dahl Compliance Consulting LLC where his practice focuses on assisting life sciences companies with their Corporate Compliance needs. As a consultant, he has built the Compliance Programs at multiple start-up pharmaceutical companies, most of which commercialized their first product during the term of his engagement. Brian also built the Corporate Compliance Programs at two top tier pharmaceutical companies - Teva Pharmaceuticals and Takeda Pharmaceuticals. Brian published two chapters - Developing and Implementing a Corporate Compliance Program and Maturing a Corporate Compliance Program - in the FDLI book Bringing Your Pharmaceutical Drug to Market. Brian earned his J.D. from the University of Iowa College of Law and his Master of Health Administration degree from the UI College of Public Health.